Clovis Oncology (CLVS) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts CLVS Hot Sheet
Join SI Premium – FREE
Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($0.50), $0.09 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $32.1 million versus the consensus estimate of $37.03 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 1st Source (SRCE) PT Raised to $92 at KBW After a 'High Quality Result'
- Bloom Energy Corp. (BE) PT Raised to $306 at Bernstein SocGen After a 'Strong beat and raise'
- Eli Lilly (LLY) PT Raised to $1,450 at Bernstein SocGen on 'International Upside Potential'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
